Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 6/20 | 0.80 |
| ▸ | MMP9 | P14780 | 6/20 | 0.80 |
| ▸ | MMP12 | P39900 | 4/20 | 0.80 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 3/20 | 0.44 |
| ▸ | MMP13 | P45452 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | MMP7 | P09237 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8403058 | 1.00 | MMP2 (0.80) | MMP2MMP9MMP12ADAM17MMP1 | |
| SCHEMBL5998380 | 0.89 | MMP2 (0.73) | MMP2MMP9MMP12ADAM17MMP1 | |
| SCHEMBL5998377 | 0.89 | MMP2 (0.73) | MMP2MMP9MMP12ADAM17MMP1 | |
| SCHEMBL5997913 | 0.89 | MMP2 (1.00) | MMP2MMP9MMP12ADAM17MMP1 | |
| SCHEMBL5997918 | 0.89 | MMP2 (1.00) | MMP2MMP9MMP12ADAM17MMP1 | |
| SCHEMBL2378490 | 0.89 | MMP2 (0.72) | MMP2MMP9MMP12ADAM17MMP1 | |
| SCHEMBL5998355 | 0.89 | MMP2 (0.72) | MMP2MMP9MMP12ADAM17MMP1 | |
| SCHEMBL5998467 | 0.89 | MMP2 (0.72) | MMP2MMP9MMP12ADAM17MMP1 | |
| SCHEMBL3043179 | 0.89 | MMP2 (0.72) | MMP2MMP9MMP12ADAM17MMP1 | |
| SCHEMBL7739858 | 0.87 | MMP2 (0.69) | MMP2MMP9MMP12ADAM17MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207569-A1 | Methods for the treatment of liver diseases | CONATUS PHARMACEUTICALS, INC. | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207569-A1 | Methods for the treatment of liver diseases | MMP1, PYGL, MMP8 | MMP2 8/4885MMP9 24/4885MMP12 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.